Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and sells a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. It offers Valeo silicon nitride interbody spinal fusion devices for use in the cervical and thoracolumbar areas of the spine; and a line of non-silicon nitride spinal fusion products. The company also develops femoral heads for use in total hip replacements; and femoral condyle components for use in total knee replacements. It markets and sells its products to surgeons and hospitals directly, as well as through a network of independent sales distributors. Amedica Corporation ...
1885 West 2100 South
Salt Lake City, UT 84119
Founded in 1996
Amedica Corporation Announces Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2015 ; Provides Financial Guidance for the Year 2015
May 7 15
Amedica Corporation announced unaudited consolidated earnings results for first quarter ended March 31, 2015. For the quarter, the company reported product revenue of $4,743,000, loss from operations of $4,006,000, net loss before income taxes of $5,381,000, net comprehensive loss of $5,381,000 or $0.2 per basic and diluted share, adjusted LBITDA of $2,880,000 compared to the product revenue of $5,780,000, loss from operations of $4,056,000, net loss before income taxes of $4,713,000, net comprehensive loss of $4,713,000 or $0.79 per basic and diluted share, adjusted LBITDA of $2,107,000 for the same quarter a year ago. Total product revenue decreased by 18% during the first quarter of 2015, primarily attributable to a 37% decrease, or $1.2 million, in the company's non-silicon nitride business due to lower metals sales. This decrease was partially offset by a 7% increase in silicon nitride ceramic product revenue over the prior-year period.
The company revised its previously stated estimates of increased 2015 silicon nitride sales in 2015 to 15-20% growth, thus equating to a total annual revenue range of $19 million - $20 million. Due to the estimated decline in annual revenue, the company expects the impact from the previously announced financial and operational alignment actions to deliver $5 - $7 million of annualized operating profit benefit. These changes are anticipated to reduce total cash burn, increase financial sustainability, and strengthen the balance sheet, positioning the company to maintain compliance with all debt covenants into fourth quarter of this year and become operating cash flow breakeven during the second half of 2016.
Amedica Corporation Presents at 5th LD Micro Invitational Conference, Jun-03-2015 10:00 AM
May 7 15
Amedica Corporation Presents at 5th LD Micro Invitational Conference, Jun-03-2015 10:00 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States. Speakers: Sonny Bal, Chairman and CEO.
Amedica Corporation to Report Q1, 2015 Results on May 07, 2015
Apr 23 15
Amedica Corporation announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on May 07, 2015